The industry has experienced a sustained period of change since its blockbuster heyday in the 1990s and continues to evolve, with significant ramifications for new pharmaceutical launches.<
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS